Biomarkers beyond BNP and Troponin
|
|
- Dora Quinn
- 5 years ago
- Views:
Transcription
1 Biomarkers beyond BNP and Troponin Alan Maisel, MD Professor of Medicine, University of California, San Diego Director, Coronary Care Unit and Heart Failure Program San Diego Veterans Hospital
2 Disclosures Consultant: Alere BG Medicine EFG diagnostics Critical Diagnostics Research: Abbott Alere Nexus Novartis BG medicine Siemens
3 The Ideal Biomarker Sensitive and specific Reflects disease severity Correlates with prognosis Should aid in clinical decision making Either highly sensitive (diagnosis) OR highly specific (treatment effect) Reflects abnormal physiology/biochemistry Prognosis is most meaningful if level is clinically actionable Should be used as a basis for specific biomarker guided-therapy Level should decrease following effective therapy Bio-monitoring during treatment is an effective surrogate of improvement Maisel, JACC 2011
4
5 The Differential Diagnosis of an Elevated Natriuretic Peptide Unrecognized HF Prior HF LVH Valvular heart disease Atrial fibrillation Advancing age Myocarditis ACS Pulmonary hypertension Congenital heart disease Anemia Pulmonary embolism Cardiac surgery Sleep apnea Critical illness Sepsis Burns Renal failure Toxic-metabolic insults
6 NEW KIDS ON THE BLOCKprognostic biomarkers in acute heart failure Adrenomedulin procalcitonin ST-2 troponin Galactin-3 NGAL Co-peptin-
7 Pressure from Hospital Administration? Novel tools and strategies are available now to assist physicians in reducing readmission and improving patient care
8 Why aren t we using Are they too expensive? Aren t they available everywhere now? Don t they help us understand pathophysiology? biomarkers?
9 Surely they can t be as expensive as other tests. Well, Bob, it looks like a paper cut, but just to be sure. Let s get an echo.
10 A CALL TO ACTION:THE TIME IS NOW GOOD BIOMARKERS ARE AVAILABLE NATRIURETIC PEPTIDES TROPONIN NGAL PCT GALECTIN-3 ST-2
11 Heart Failure + infection Heart failure plus pneumonia is present about 10-15% of time Heart failure plus any infection may occur in up to 20% of hospitalized heart failure patients. Hospital Mortality may be up to 20% (versus 5%) in heart failure patients with untreated infections
12 PCT Level Increase = Increased Significance of Bacterial Infection In critically ill patients, PCT levels elevate in correlation to the severity of bacterial infection In healthy people, PCT concentration are found below 0.05ng/ml Concentrations exceeding 0.5ng/ml can be interpreted as abnormal
13 PCT for therapeutic stewardship -> Shortening AB therapy in patients with CAP Prospective interventional trial: 302 patients Tailoring of AB treatment to the individual patient needs Reduction of average treatment duration from 12 to 5 days. Same outcome! (Safety) Christ-Crain M et al. Am J Respir Crit Care Med Apr 7
14
15 AHF, no Pneumonia (n=539) BNP [ng/ml] no AHF, no Pneumonia (n=947) AHF and Pneumonia (n=29) Pneumonia, no AHF (n=126) PCT [ng/ml]
16 Kaplan-Meier plot for antibiotic treatment (yes or no) and all cause mortality within 90 days A. all patients with HF B. lowest quintile, patients with PCT levels below ng/m C, p=0.356), between and D. highest quintile, p=0.046), adjusted for covariates Maisel et al in prep
17 Galectin-3 mediated heart failure Pre-clinical animal model of hypertensive heart failure Increased Gal-3 expression in rats that developed HF Galectin-3 Non-Transgenic Comp. Heart Failure Pericardial infusion of recombinant Gal-3 in healthy rats Increased cardiac fibroblast proliferation Increased collagen production Reduced LVEF Galectin-3 is a mediator of cardiac fibrogenesis resulting in heat failure development and progression Sharma UC, et al. Circulation. 2004; 110:
18 Segmenting a Sub-type of Heart Failure Based on the Phenotype of Galectin 3 GALECTIN-3 MEDIATED HF HF GENERAL POPULATION Active scarring (fibrosis) and adverse remodeling Inherently progressive ~30-50% are at greatest risk of adverse outcome NON-GALECTIN-3 MEDIATED HF Heterogeneous etiology Not inherently progressive ~50-70% are at lower risk of adverse outcome
19 Who has a + Gal-3 phenotype? Maybe 15% of population! Means you could be ticking time bomb if you allow cardiac risk factors to occur (Htn, Diabetes, CAD, MI,HF) The patients need aggressive follow-up
20 Galectin-3 Mediated HF is Inherently Progressive Illustration of two clinically very similar patients with different galectin-3 levels and dramatically different clinical paths 8.5 ng/ml Patient A SEVERITY OF DISEASE CARDIAC FUNCTION 36.4 ng/ml Patient B DEATH TIME 20
21 HEPATITIS Syndromal diagnosis Phenotyping, specific tests specified diagnosis Hepatitis B Hepatitis C Epstein Barr Virus (EBV) Antiviral agents, e.g. lamivudine Interferon Ganclicovir
22 ACE-inhibitors Beta blockers Mineralocorticoid Receptor Antagonists CRT/ICD HEART FAILURE Syndromal diagnosis Phenotyping, specific tests specified diagnosis CAD Hypertension Cardiomyopathy
23 HEART FAILURE Syndromal diagnosis Phenotyping, specific tests specified diagnosis Galectin-3 Conduction disturbance Renin Anti Galectin-3 agents CRT Renin inhibitors, e.g. aliskiren
24 Galectin-3 and Natriuretic Peptides Galectin-3 BNP/NT-proBNP Biology Indicator of cardiac fibrosis Indicator of cardiac stress Short Term Variability - Relatively stable - Not affected by acute decompensation - Marked variability - Elevation with acute decompensation Response to HF Treatments In HF Management Medicare Reimbursement Not immediately affected by acute HF treatment Aid in Rx and risk stratification (mechanism: indication of the pathologic progression of HF) Yes Can be reduced with acute HF treatment in some patients Aid in Dx, Rx and risk stratification (mechanism: indication of cardiac stress in HF) Yes 24
25 Gal 3 is independent and additive to NPs in risk prediction HF-ACTION; all-cause mortality and allcause hospitalization COACH; 1-year all-cause mortality HF-ACTION: Felker GM, et al. Circ Heart Fail. 2012; 5: 72-8 COACH: de Boer RA, et al. Ann Med. 2011; 43:
26 Galectin-3 Consistently Predicts Probability of Re-hospitalization in Three Studies COACH PRIDE p=0.017 UMD H23258 P<0.001 de Boer RA, et al. J Cardiac Fail 2011;17:S93 26
27 Two cut-offs for risk PROGNOSTIC UNCERTAINTY Probability (RRT) Gal-3 <9 ng/ml High NPV Rule out Grey area Galectin 3 Rule in Gal-3 >17.8 ng/ml High PPV
28 Patients presenting with dyspnea to ED Galectin-3 < 9.5ng/ml Low risk Diagnosis: Acute Heart Failure Galectin ng/ml Galectin-3 > 17.8 ng/ml High risk BNP < 400 pg/ml BNP 400 pg/ml BNP < 400 pg/ml BNP 400 pg/ml Diurese and discharge Observation Unit and D/C with f/u if responds well and low risk Admit to hospital
29 What would you do in the hospital with a high Gal-3 patient? Vigorous treatment and monitoring of fluid, BNP levels Aggressive uptitration of oral medication Early follow-up Home health monitoring Consider CRT/AICD MRA inhibitors?citrus pectin
30 SERUM LEVELS OF COLLAGEN BIOMARKERS Placebo Eplerenone * Iraqi W et al. Circulation 2009;119: *PINP: Pro Collagen type 1 N-terminal propeptide
31
32
33 Cox Regression: Initiation of spironolactone HR=0.362, p=0.027 Cox Regression: Continuation of spironolactone HR=0.294, p=0.02
34 Cox Regression: Spironolactone therapy HR=0.779, p=0.803 Cox Regression: Spironolactone therapy HR=0.519, p=0.037 Galectin-3 cutoff: 17.8ng/mL
35 What is ST2? ST2 is a member of the Interleukin-1 receptor family, and is formally known as interleukin 1 receptor like 1 (IL1RL-1) Exists in two main isoforms through alternative splicing and processing ST2L is a membrane-bound isoform with 3 extracellular IgG domains, a single transmembrane domain, and an intracellular domain ST2 is a soluble, circulating isoform, lacks the transmembrane and intracellular domains It was considered an orphan receptor until identification of its ligand, IL-33, in 2005 Was first reported in 1989, but its function was not well elucidated Investigation revealed its participation in inflammatory processes, particularly regarding mast cells, type 2 CD4+ T-helper cells, and the production of Th2-associated cytokines Initially associated with disease entities such as asthma, pulmonary fibrosis, rheumatoid arthritis, collagen vascular diseases, and septic shock In 2002, Richard Lee at Harvard B&W reported ST2 expression in response to myocardial stress and injury ST2 is expressed by cardiac tissue. Subsequently ST2 was shown to be actively involved in the fibrotic response to illness or injury.
36 Pro-IL-33 Fibroblast Caspase-1 ST2: A DECOY RECEPTOR Myocyte IRAK IL-33 ST2L MyD88 ERK NFκB sst2 CARDIOPROTECTION Adapted from Kakkar et al. Nat Rev Drug Discov 2008
37 ST2 in Cardiac Medicine Is NOT a stretch marker Is NOT an inflammatory marker Is a marker of fibrosis and cardiac remodeling providing prognostic guidance Clinical use is not effected by typical confounders such as obesity and renal impairment!!!
38 Reference Analysis and Cutpoint Selection Level Primary Reference Cohort 1 Confirmation Reference Cohort 2 Mean (SD) 20.9 (9.3) 22.4 (8.7) Min th percentile th percentile (median) th percentile th percentile th percentile* th percentile Max N 490 3,450 *cutpoint concentration for assessment of risk in patients with heart failure was selected at the ~95 th precentile of normal 1 Lu et al. 2010, 2 Coglianese et al. 2012
39 ST2 Concentrations and 1-Yr Mortality in Acute HF: As ST2 levels increase, so does risk One-Year mortality >50% for highest decile Rehman et al. Correlates of ST2 in Acute HF JACC Vol. 52, No. 18,
40 In ADHF Risk is Much Higher if ST2 >35 ng/ml
41 Additive Value of ST2 to NT-proBNP: Acute HF Cumulative Hazard Both sst2 and NT-proBNP elevated (n=276) Only sst2 elevated (n=95) Only NT-proBNP elevated (n=54) Neither elevated (n=168) P < Reclassification Days from Enrollment Patient would have been classified as moderate risk with only NT-proBNP, but is considered high risk with the addition of ST2. Rehman SR, van Kimmenade RR, Januzzi JL. Circulation. 2008;118:S_871.
42 Additive Value of ST2 to NT-proBNP: Chronic HF Category Death Rate HR (95% CI) p ST2 35 ng/ml NT-proBNP median ST2 35 ng/ml NT-proBNP >median ST2 >35 ng/ml NT-proBNP median ST2 >35 ng/ml NT-proBNP >median 9.0% 1 NA 23.3% 2.87 ( ) < % 2.70 ( ) % 5.59 ( ) <0.001 Results from HF-ACTION chronic, ambulatory HF study cohort. Median NT-proBNP concentration is 852 pg/ml in this study. Study follow-up period of 4 years. Risk is higher if either marker is elevated and highest if both makers are elevated Felker, et al. 2013, Circ HF
43 Serial ST2 Measurements for In-Patient Monitoring (SDVA): Mortality N=35 N=115 N= 150 ST2 Values Shown Using 1 st Generation Research Assay. Boisot et al. J Card Failure 2008
44 Serial ST2 Measurements Categorize Responder Status Low Risk Patients COX Regression Analysis For every 10% ST2 change HR 1.04, p=0.03 High Risk Patients Adjustment for ADHERE Risk Factors and BNP change. Breidthardt, et al JCF
45 ST2 Levels Predict Response to Treatment: BB 1 Cumulative survival BB treated ST2 responder BB treated ST2 non-responder untreated ST2 responder p=0.62 p=0.1 Risk is not absolute! It can be attenuated!! 4 untreated ST2 non-responder Days Breidthardt, et al JCF
46 Val-HeFT: Methods and Results The Valsartan Heart Failure Trial (Val- HeFT) randomized 5010 patients with NYHA class II-IV HF to valsartan or placebo. ST2 was measured in 1,650 US patients at baseline, 1,346 at 4 months and in 1,097 at 12 months after randomization. Snider et al. HFA poster #677, 2012
47 Change in ST2 and Outcomes: Val-HeFT Study Category HR CI p High-High 1.7 Low-High 1.9 High-Low Low-Low Fully adjusted hazard ratios after correction for 22 clinical variables. Conclusion: Change in ST2 over time was independently and significantly related to the subsequent risks of mortality, first morbid event or hospitalization for HF. 72% of patients had persistently low ST2 Another 8% moved from high risk to low risk 20% of patients had persistently high or transition to high ST2
48 Clinical Characteristics of AHFS Patients Data on approximately 200,000 patients Median age (years) 75 Women >50% Hx of Atrial Fibrillation Preserved Ejection Fraction 30% 50% Hx of CAD 60% SBP >140 mm Hg 50% Hx of Hypertension 70% SBP mm Hg 45% Hx of Diabetes 40% SBP <90 mm Hg 5% Adams KF, et al. Am Heart J. 2005;149: 209. Cleland JGF et al. Eur Heart J. 2003; 24: 442; Fonarow GC, et al. J Am Coll Cardiol. 2004; 844 4A. Renal abnormalities 30%
49 CardioRenal Syndrome Type 1: Creatinine Increase in Acute HF Patients Creatinine is a measure of kidney function. An increasing creatinine over time means that the kidney was injured and has lost function. The graph below shows how Cr increases in hospitalized HF patients. 0.1 % Cr X Type 1 CardioRenal Syndrome Also know as: X X X X X X X X X X X X X X Worsening Renal Function (WRF) or Acute Kidney Injury (AKI) Days Cr, serum creatinine. Gottlieb SS et al. J Card Fail. 2002;8:136. Smith G, J Card Fail Feb;9(1):13-25
50 Iatrogenic causes of AKI in HF patients To much Diuretic ACE, ARB, Aldo Blockers Contrast Antibiotics
51 Outcome Incidence WRF ~ 28%; 90% occurred within 7 days No WRF (n=1212, 72%) WRF (n=469, 28%) Adj Hospital Death (%) d Death (%) m Death Hospital Stay (d) Hospital Cost ($) 6,327 8,085 1,758 Krumholz et al Am J Cardiol 2000
52 Ronco C et al. J Am Coll Cardiol 2008; 52: Cardiorenal Syndrome (CRS) General Definition: A pathophysiologic disorder of the heart and kidneys whereby acute or chronic dysfunction in one organ may induce acute or chronic dysfunction in the other organ CRS Type I (Acute Cardiorenal Syndrome) Abrupt worsening of cardiac function (e.g. acute cardiogenic shock or decompensated congestive heart failure) leading to acute kidney injury CRS Type II (Chronic Cardiorenal Syndrome) Chronic abnormalities in cardiac function (e.g. chronic congestive heart failure) causing progressive and permanent chronic kidney disease CRS Type III (Acute Renocardiac Syndrome) Abrupt worsening of renal function (e.g. acute kidney ischaemia or glomerulonephritis) causing acute cardiac disorder (e.g. heart failure, arrhythmia, ischemia) CRS Type IV (Chronic Renocardiac Syndrome) Chronic kidney disease (e.g. chronic glomerular disease) contributing to decreased cardiac function, cardiac hypertrophy and/or increased risk of adverse cardiovascular events CRS Type V (Secondary Cardiorenal Syndrome) Systemic condition (e.g. diabetes mellitus, sepsis) causing both cardiac and renal dysfunction
53 Approach in Acute Kidney Injury Identification of Risk patients Primary prevention Early detection of AKI Reduction of Morbidity and Mortality? Secondary prevention
54 AMI versus AKI Period 1960s 1970s 1980s 1990s 2000s Acute Myocardial Infarction LDH CPK, myoglobin CK-MB Troponin T Troponin I Multiple Therapies 50% Mortality
55 AMI versus AKI Period Acute Myocardial Infarction Acute Kidney Injury 1960s LDH SCr 1970s CPK, myoglobin SCr 1980s CK-MB SCr 1990s Troponin T SCr 2000s Troponin I SCr Multiple Therapies 50% Mortality Supportive Care High Mortality Need early biomarkers for better treatment of AKI
56 Up to 50% of kidney function may be lost before serum creatinine even begins to rise
57 The promise of biomarkers for AKI The nephrologist s troponin Measured in urine or serum Early management (goaldirected therapy) Development of New therapeutic strategies
58 Protein Biomarkers for the Early Detection of Acute Kidney Injury Biomarker Cystatin C KIM-1 NGAL (lipocalin) NHE3 Cytokines (IL-6, IL-8, IL-18) Actin-actin depolymerizing F α-gst Π-GST L-FABP Netrin-1 Keratin-derived chemokine Associated Injury Proximal tubule injury Ischemia and nephrotoxins Ischemia and nephrotoxins Ischemia, pre-renal, post-renal AKI Toxic, delayed graft function Ischemia and delayed graft function Proximal tubule injury, acute rejection Distal tubule injury, acute rejection Ischemia and nephrotoxins Ischemia and nephrotoxins, sepsis Ischemia and delayed graft function GST = glutathione S-transferase; IL = interleukin; KIM = kidney injury molecule; L-FABP = L-type fatty acid binding protein; NGAL = neutrophil gelatinase-associated lipocalin; NHE = sodium-hydrogen exchanger.
59 Heart Failure Cardiac surgery Radiocontrast Trauma ICU Kidney transplant NGAL IgA nephropathy CKD
60 S- and U-NGAL in children after cardiopulmonary bypass (n=71) 28% dev AKI Mishra J et al. Lancet 2005;365.
61 What can NGAL detect? NGAL Creatinine Marker of Renal Injury High Sensitivity for Injury Moderate Specificity for underlying nephropathy
62 AKI SPECTRUM Normal markers; no AKI NO STRUCTURAL OR FUNCTIONAL INJURY STRUCTURAL INJURY BUT NORMAL FUNCTION Normal Cr NGAL, Early AKI Normal NGAL, Cr Pre-renal AKI FUNCTIONAL LOSS BUT NORMAL STRUCTURE BOTH STRUCTURAL AND FUNCTIONAL LOSS Cr NGAL, Establishe d AKI
63 Grey Zone Probability (RRT) BM <xx High NPV Rule out PROGNOSTIC UNCERTAINTY Rule in Grey area Biomarker X BM >XX High PPV
64 Clinical Scenario: Year 2014 NGAL level Diagnosis Intervention <100 ng/ml No AKI Routine care
65 NGAL level Diagnosis Intervention <100 ng/ml No renal injury Routine care ng/ml High risk for AKI Hold ACE Hold ARB Hold Aldo blockers No contrast No renal toxic antibiotics No NSAIDS Judicious diuretics
66 NGAL level Diagnosis Intervention <100 ng/ml No renal injury Routine care ng/ml High risk for AKI Hold ACE Hold ARB Hold Aldo blockers No contrast No renal toxic antibiotics No NSAIDS Judicious diuretics >350 ng/ml High risk for AKI, dialysis and death ICU admit Consider ultrafiltration
67
68 Discharge levels of markers Maisal et al Eur J Heart Fail 2011
69 Group HR p NGAL <100 BNP <330 NGAL <100 BNP >330 NGAL >100 BNP <330 NGAL >100 BNP > <0.001 Maisal et al Eur J Heart Fail 2011
ST2 in Heart Failure. ST2 as a Cardiovascular Biomarker. Competitive Model of ST2/IL-33 Signaling. ST2 and IL-33: Cardioprotective
ST2 as a Cardiovascular Biomarker Lori B. Daniels, MD, MAS, FACC Professor of Medicine Director, Coronary Care Unit University of California, San Diego ST2 and IL-33: Cardioprotective ST2: member of the
More informationHeart Failure and Cardio-Renal Syndrome 1: Pathophysiology. Biomarkers of Renal Injury and Dysfunction
CRRT 2011 San Diego, CA 22-25 February 2011 Heart Failure and Cardio-Renal Syndrome 1: Pathophysiology Biomarkers of Renal Injury and Dysfunction Dinna Cruz, M.D., M.P.H. Department of Nephrology San Bortolo
More informationRisk Stratification in Heart Failure: The Role of Emerging Biomarkers
Risk Stratification in Heart Failure: The Role of Emerging Biomarkers David G. Grenache, PhD Associate Professor of Pathology, University of Utah Medical Director, ARUP Laboratories Salt Lake City, UT
More information10 years evaluation of soluble ST2 level and incidence of diastolic
10 years evaluation of soluble ST2 level and incidence of diastolic dysfunction in EGAT study population Wisuit Katekao, MD Prin Vathesatogkit, MD Oraporn See, MD Sukit Yamwong, MD Piyamitr Sritara, MD
More informationDoppler ultrasound, see Ultrasonography. Magnetic resonance imaging (MRI), kidney oxygenation assessment 75
Subject Index Acidemia, cardiorenal syndrome type 3 146 Acute Dialysis Quality Initiative (ADQI) acute kidney injury biomarkers, see Acute kidney injury; specific biomarkers cardiorenal syndrome, see specific
More informationBiomarkers Now and in the Future of Emergency Medicine- TIME TO USE sst2 Alan S. Maisel MD FACC Professor of Medicine, Emeritus University of
Biomarkers Now and in the Future of Emergency Medicine- TIME TO USE sst2 Alan S. Maisel MD FACC Professor of Medicine, Emeritus University of California, San Diego, Chest Pain, Shortness of breath: We
More informationΒΙΟΔΕΙΚΤΕΣ ΣΤΗΝ ΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ. ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Καθηγητής Καρδιολογίας
ΕΘΝΙΚΟ ΚΑΙ ΚΑΠΟΔΙΣΤΡΙΑΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΑΘΗΝΩΝ ΙΑΤΡΙΚΗ ΣΧΟΛΗ Ά ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ Διευθυντής: Καθηγητής Δημήτριος Τούσουλης ΒΙΟΔΕΙΚΤΕΣ ΣΤΗΝ ΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Καθηγητής Καρδιολογίας
More informationPivotal Role of Renal Function in Acute Heart failure
Pivotal Role of Renal Function in Acute Heart failure Doron Aronson MD, FESC Department of Cardiology RAMBAM Health Care Campus Haifa, Israel Classification and definitions of cardiorenal syndromes CRS
More informationUpdate on Biomarkers in Heart Failure. Professor T A McDonagh, King s College Hospital. London
Update on Biomarkers in Heart Failure Professor T A McDonagh, King s College Hospital. London Known Knowns,,,, for Biomarkers in HF Natriuretic Peptides Troponins BNP... ANP/BNP/ in CHF First to be discovered
More informationRuolo dei Marcatori Bioumorali nello scompenso cardiaco
Ruolo dei Marcatori Bioumorali nello scompenso cardiaco Head Emergency Medicine Sant Andrea Hospital Director Postgraduate School of Emergency Medicine Faculty od Medicine and Psycology Sapienza University
More informationPitfalls in the use of biomarkers
Pitfalls in the use of biomarkers Alan Maisel MD Professor of Medicine, University of California, San Diego Director Coronary Care Unit And Heart Failure Program San Diego Veterans Hospital Disclosure
More informationNatriuretic Peptide Guided Therapy for Heart Failure
Natriuretic Peptide Guided Therapy for Heart Failure Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research Duke Clinical Research Institute Disclosures Research Grants
More informationBiomarkers in the Age of Sacubitril/Valsa rten: Has the PARADIGM Changed
Biomarkers in the Age of Sacubitril/Valsa rten: Has the PARADIGM Changed Alan S. Maisel MD FACC Professor of Medicine, University of California, San Diego, Director, CCU and Heart Failure Program San Diego
More informationThe clinical value of natriuretic peptide testing in heart failure
The clinical value of natriuretic peptide testing in heart failure James L. Januzzi, Jr, MD, FACC, FESC Associate Professor of Medicine Harvard Medical School Roman W. DeSanctis Endowed Clinical Scholar
More informationΒιοδείκτες στην καρδιακή ανεπάρκεια διαγνωστικά και θεραπευτικά δεδομένα. Χριστίνα Χρυσοχόου Επιμ Α Α Παν. Καρδιολογικής Κλινικής, ΙΓΝΑ
Βιοδείκτες στην καρδιακή ανεπάρκεια διαγνωστικά και θεραπευτικά δεδομένα Χριστίνα Χρυσοχόου Επιμ Α Α Παν. Καρδιολογικής Κλινικής, ΙΓΝΑ Παθοφυσιολογία καρδιακής ανεπάρκειας Kaye and Krum Nature Reviews
More informationFrom PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group
From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF
More informationNatriuretic Peptides The Cardiologists View. Christopher defilippi, MD University of Maryland Baltimore, MD, USA
Natriuretic Peptides The Cardiologists View Christopher defilippi, MD University of Maryland Baltimore, MD, USA Disclosures Research support: Alere, BG Medicine, Critical Diagnostics, Roche Diagnostics,
More informationHeart Failure and Renal Failure. Gerasimos Filippatos, MD, FESC, FHFA President HFA
Heart Failure and Renal Failure Gerasimos Filippatos, MD, FESC, FHFA President HFA Definition Epidemiology Pathophysiology Management (?) Recommendations for NHLBI in cardiorenal interactions related to
More informationManagement of chronic heart failure: update J. Parissis Attikon University Hospital
Management of chronic heart failure: update 2015 J. Parissis Attikon University Hospital Disclosures: received honoraria for lectures from Servier, Pfizer, Novartis Discharges in Thousands Heart Failure
More informationBiomarker-guided HF: What have we learned (so far)?
Biomarker-guided HF: What have we learned (so far)? James L. Januzzi, Jr, MD, FACC, FESC Associate Professor of Medicine Harvard Medical School Director, Cardiac ICU Massachusetts General Hospital DECLARATION
More informationA Guide to Proper Utilization of Biomarkers
A Guide to Proper Utilization of Biomarkers DR. ABEER BAKHSH CONSULTANT CARDIOLOGIST, ADVANCE HEART FAILURE KING FAHD ARMED FORCES HOSPITAL JEDDAH, SAUDI ARABIA Objective: Mechanism of myocardial injury
More informationUPDATES IN MANAGEMENT OF HF
UPDATES IN MANAGEMENT OF HF Jennifer R Brown MD, MS Heart Failure Specialist Medstar Cardiology Associates DC ACP Meeting Fall 2017 Disclosures: speaker bureau for novartis speaker bureau for actelion
More informationPearls in Acute Heart Failure Management
Pearls in Acute Heart Failure Management Best Practices Juan M. Aranda Jr., M.D. Professor of Medicine Medical Director of Heart Failure/ Transplant Program University of Florida College of Medicine Disclosures:
More informationThe ACC Heart Failure Guidelines
The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA
More informationRecognizing and Treating Patients with the Cardio-Renal Syndrome
Recognizing and Treating Patients with the Cardio-Renal Syndrome Joachim H. Ix, MD, MAS, FASN Professor of Medicine Chief; Division of Nephrology-Hypertension University of California San Diego 1 Conflicts
More informationCardiorenal Biomarkers and Heart Failure. Nicholas Wettersten, MD April 7 th, 2017
Cardiorenal Biomarkers and Heart Failure Nicholas Wettersten, MD April 7 th, 2017 Disclosures Still none, but looking for some Acute Kidney Injury Biomarkers 547 in 2015 4112 as of March 2017 Case 1 60
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationUpdates in Congestive Heart Failure
Updates in Congestive Heart Failure GREGORY YOST, DO JOHNSTOWN CARDIOVASCULAR ASSOCIATES 1/28/2018 Disclosures Edwards speaker on Sapien3 valves (TAVR) Stages A-D and NYHA Classes I-IV Stage A: High risk
More informationACUTE HEART FAILURE. Julie Gorchynski MD, MSc, FACEP, FAAEM. Department of Emergency Medicine Emergency Residency Program UTHSC, San Antonio TCEP 2014
ACUTE HEART FAILURE Julie Gorchynski MD, MSc, FACEP, FAAEM Department of Emergency Medicine Emergency Residency Program UTHSC, San Antonio TCEP 2014 No disclosures Objectives Overview Cases Current Therapy
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More information6/6/17. Heart Failure and Natriuretic Peptides. Learning objectives
Heart Failure and Natriuretic Peptides Maria-Magdalena Patru, MD, PhD Director, Medical and Scientific Affairs This promotional educational activity is brought to you by Ortho-Clinical Diagnostics, Inc.
More informationHeart Failure Biomarkers: Advances in Diagnostics and Therapeutics
Heart Failure Biomarkers: Advances in Diagnostics and Therapeutics Michael Felker, MD, MHS, FACC, FAHA Associate Professor of Medicine Director, Heart Failure Section Disclosures Consulting and/or Grant
More informationRole of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association
Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association We combed through both guidelines and summarized 3 recommendations
More informationCardiorenal Syndrome Prof. Dr. Bülent ALTUN Hacettepe University Faculty of Medicine Department of Internal Medicine Division of Nephrology
Cardiorenal Syndrome Prof. Dr. Bülent ALTUN Hacettepe University Faculty of Medicine Department of Internal Medicine Division of Nephrology Heart and Kidney The kidney yin dominates water, The heart yang
More informationAcute heart failure syndromes: clinical challenges. Pathophysiology. ESC Congress August. Paris, France. Marco Metra
ESC Congress 2011 27-31 August. Paris, France. Acute heart failure syndromes: clinical challenges. Pathophysiology Marco Metra Cardiology, Dept. Of experimental and applied medicine. University of Brescia.
More informationClinical Review Criteria Galectin-3 Blood Assay Test
Clinical Review Criteria Galectin-3 Blood Assay Test Kaiser Foundation Health Plan of Washington NOTICE: Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options,
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationOvercoming the Cardiorenal Syndrome
Overcoming the Cardiorenal Syndrome October 29, 2016 Randall C Starling MD MPH FACC FESC FHFSA FHFA Professor of Medicine Heart & Vascular Institute Cleveland Clinic Lerner College of Medicine Cleveland
More informationStopping the Revolving Door of ADHF
Stopping the Revolving Door of ADHF Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center
More informationHeart Failure Guidelines For your Daily Practice
Heart Failure Guidelines For your Daily Practice Juan M. Aranda, Jr., MD, FACC, FHFSA Professor of Medicine Director of Heart Failure and Cardiac Transplantation University of Florida College of Medicine
More informationHEART FAILURE PATIENT MANAGEMENT. To The Power of 2!
HEART FAILURE PATIENT MANAGEMENT To The Power of 2! Put The Power of 2 To Work For You! THE PRESAGE ST2 ASSAY is a simple blood test that aids physicians in risk assessment of heart failure patients. Elevated
More informationHFpEF. April 26, 2018
HFpEF April 26, 2018 (J Am Coll Cardiol 2017;70:2476 86) HFpEF 50% or more (40-71%) of patients with CHF have preserved LV systolic function. HFpEF is an increasingly frequent hospital discharge. Outcomes
More informationHeart Failure. Guillaume Jondeau Hôpital Bichat, Paris, France
Heart Failure Guillaume Jondeau Hôpital Bichat, Paris, France Epidemiology Importance of PEF Europe I-PREFER study. Abstract: 2835 Prevalence of HF Preserved LV systolic Function older (65 vs 62 y, p
More information2017 ACC/AHA/HFSA HF guidelines. Advances in the Use of Biomarkers in Heart Failure Patients. Outline
Advances in the Use of Biomarkers in Heart Failure Patients Lori B. Daniels, MD, MAS, FACC, FAHA Professor of Medicine Director, Cardiovascular Intensive Care Unit Sulpizio Cardiovascular Center UC San
More informationBiomarkers in the Assessment of Congestive Heart Failure
Biomarkers in the Assessment of Congestive Heart Failure Mid-Regional pro-adrenomedullin (MR-proADM) vs BNP & NT-proBNP as Prognosticator in Heart Failure Patients: Results of the BACH Multinational Trial
More informationNGAL Connect to the kidneys
NGAL Connect to the kidneys Acute kidney injury (AKI) An imposing medical and diagnostic challenge >13 million AKI patients each year ~ 30% with fatal outcome Cardiac surgery > 1 million patients/year
More informationEditorial Staying in the Pink of Health for Patients with Cardiorenal Anemia Requires a Multidisciplinary Approach
Editorial Staying in the Pink of Health for Patients with Cardiorenal Anemia Requires a Multidisciplinary Approach Anemia and Heart Failure Ragavendra R. Baliga, MD, MBA James B. Young, MD Consulting Editors
More informationHeart Failure in Women: Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre
Heart Failure in Women: More than EF? Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre Overview Review pathophysiology as it relates to diagnosis and management Rational approach to workup:
More informationDiscovery & Validation of Kidney Injury Biomarkers
Dublin Academic Medical Centre Discovery & Validation of Kidney Injury Biomarkers Patrick Murray, MD, FASN, FRCPI, FJFICMI Professor, University College Dublin, Mater Misericordiae University Hospital,
More information6/29/2017. Role of Biomarkers in the Management of Heart Failure Patients. What s New in Biomarkers for HF Patients?
What s New in Biomarkers for HF Patients? Role of Biomarkers in the Management of Heart Failure Patients Lori B. Daniels, MD, MAS, FACC Professor of Medicine Director, Cardiovascular Intensive Care Unit
More informationBiomarkers in Heart Failure
Biomarkers in Heart Failure James L. Januzzi, Jr, MD Associate Professor of Medicine Harvard Medical School Director, Cardiac ICU Massachusetts General Hospital Disclosures Research grants for clinical
More informationBiomarkers in Acute Cardiac Disease Samir Arnaout, M.D.FESC Associate Professor of Medicine Internal Medicine i & Cardiology American University of Beirut Time course of the appearance of various markers
More informationBiomarkers for optimal management of heart failure. Cardiorenal syndrome. Veli-Pekka Harjola Helsinki University Central Hospital Helsinki, Finland
Biomarkers for optimal management of heart failure Cardiorenal syndrome Veli-Pekka Harjola Helsinki University Central Hospital Helsinki, Finland Presenter Disclosure Information V-P Harjola The following
More informationLCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection
More informationBeyond ACE-inhibitors for Heart Failure. Jacob Townsend, MD NCVH Birmingham 2015
Beyond ACE-inhibitors for Heart Failure Jacob Townsend, MD NCVH Birmingham 2015 % Decrease in Mortality Current Therapy HFrEF 0% Angiotensin receptor blocker ACE inhibitor Beta blocker Mineralocorticoid
More informationTreating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment
ESC 2012 27Aug - 3Sep, 2012, Munich, Germany Treating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment Marco Metra, MD, FESC Cardiology University
More informationMedical Management of Acute Heart Failure
Critical Care Medicine and Trauma Medical Management of Acute Heart Failure Mary O. Gray, MD, FAHA Associate Professor of Medicine University of California, San Francisco Staff Cardiologist and Training
More informationOutline. Classification by LVEF Conventional Therapy New Therapies. Ivabradine Sacubitril/valsartan
New Pharmacological Therapies for Heart Failure Mark Drazner, MD, MSc Clinical Chief of Cardiology Medical Director, CHF/VAD/Transplant James M. Wooten Chair in Cardiology UT Southwestern Medical Center
More informationTreating HF Patients with ARNI s Why, When and How?
Treating HF Patients with ARNI s Why, When and How? 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La Jolla, CA Barry Greenberg M.D. Distinguished Professor
More informationThe Dyspneic Patient in the ED Which Biomarkers should we use and how THIS COULD BE YOUR MOTHER
The Dyspneic Patient in the ED Which Biomarkers should we use and how THIS COULD BE YOUR MOTHER Diagnostic Biomarkers BNP Mid-region proanp Procalcitonin NGAL BIVA Prognostic Biomarkers Troponin Adrenomedulin
More informationMedical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece
Medical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece Disclosures Grants: ALARM investigator received research grants
More informationNovel Approaches for Recognition and Management of Life Threatening Complications of AKI and CKD: Focus on Acute Cardiorenal Syndromes
Novel Approaches for Recognition and Management of Life Threatening Complications of AKI and CKD: Focus on Acute Cardiorenal Syndromes Peter A. McCullough, MD, MPH Baylor University Medical Center, Dallas
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More informationWhat s new in the 2017 heart failure guidelines. Prof.Dr.Mehmet Birhan YILMAZ, FESC, FACC, FHFA
What s new in the 2017 heart failure guidelines Prof.Dr.Mehmet Birhan YILMAZ, FESC, FACC, FHFA Key points to remember 2017 guidelines recommend using natriuretic peptides as biomarkers to screen for heart
More informationAcute Kidney Injury for the General Surgeon
Acute Kidney Injury for the General Surgeon UCSF Postgraduate Course in General Surgery Maui, HI March 20, 2011 Epidemiology & Definition Pathophysiology Clinical Studies Management Summary Hobart W. Harris,
More informationCase Presentation. This presentation is the intellectual property of the author. Contact them for permission to reprint and/or distribute.
Worsening Renal Function in Heart Failure Patients Mark Drazner, MD, MSc Clinical Chief of Cardiology Medical Director, CHF/VAD/Transplant James M. Wooten Chair in Cardiology UT Southwestern Medical Center
More informationHFpEF, Mito or Realidad?
HFpEF, Mito or Realidad? Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center Bronx, NY
More informationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response
More informationΟξεία καρδιακή ανεπάρκεια: Ποιες παράμετροι συμβάλλουν στη διαστρωμάτωση κινδύνου των ασθενών;
Οξεία καρδιακή ανεπάρκεια: Ποιες παράμετροι συμβάλλουν στη διαστρωμάτωση κινδύνου των ασθενών; Γ. Φιλιππάτος, MD, FACC, FESC, FCCP Επ. Καθηγητής Καρδιολογίας Πανεπ. Αθηνών Clinical Outcomes in Patients
More informationAkash Ghai MD, FACC February 27, No Disclosures
Akash Ghai MD, FACC February 27, 2015 No Disclosures Epidemiology Lifetime risk is > 20% for American s older than 40 years old. > 650,000 new cases diagnosed each year. Incidence increases with age: 2%
More informationHeart Failure and Renal Disease Cardiorenal Syndrome
Advanced Heart Failure: Clinical Challenges Heart Failure and Renal Disease Cardiorenal Syndrome 17 th Apr 2015 Ju-Hee Lee, M.D Cardiovascular Center, Chungbuk National University Hospital Chungbuk National
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationCardiorenal Syndrome
SOCIEDAD ARGENTINA DE CARDIOLOGIA Cardiorenal Syndrome Joint session ESC-SAC ESC Congress 2012, Munich César A. Belziti Hospital Italiano de Buenos Aires I have no conflicts of interest to declare Cardiorenal
More informationCardio-Renal Syndrome in Acute Heart Failure:
Cardio-Renal Syndrome in Acute Heart Failure: Target for Therapy Marvin A. Konstam, M.D. Research support and/or consulting relevant to this lecture: Merck, Otsuka, Johnson & Johnson; Amgen; Cardiokine
More informationThe Therapeutic Potential of Novel Approaches to RAAS. Professor of Medicine University of California, San Diego
The Therapeutic Potential of Novel Approaches to RAAS Inhibition in Heart Failure Barry Greenberg, M.D. Professor of Medicine University of California, San Diego Chain of Events Leading to End-Stage Heart
More informationHeart failure (HF) is a complex clinical syndrome that results in the. impairment of the heart s ability to fill or to pump out blood.
Introduction: Heart failure (HF) is a complex clinical syndrome that results in the impairment of the heart s ability to fill or to pump out blood. As of 2013, an estimated 5.8 million people in the United
More informationTHE KIDNEY IN HYPOTENSIVE STATES. Benita S. Padilla, M.D.
THE KIDNEY IN HYPOTENSIVE STATES Benita S. Padilla, M.D. Objectives To discuss what happens when the kidney encounters low perfusion To discuss new developments and clinical application points in two scenarios
More informationThe Approach to Patients with Heart Failure and Mid-Range (40-50%) Ejection Fraction (HFmrEF)
The Approach to Patients with Heart Failure and Mid-Range (40-50%) Ejection Fraction (HFmrEF) 22 nd Annual Heart Failure 2018 an Update on Therapy April 21, 2018 Los Angeles, CA Barry Greenberg, M.D. Distinguished
More informationCitation. What is New in the 2013 ACC/AHA HF Guideline. Dimensions in Heart and Vascular Care Penn State Heart and Vascular Institute
What is New in the 2013 ACC/AHA HF Guideline Dimensions in Heart and Vascular Care Penn State Heart and Vascular nstitute Friday October 18, 2013 Barry S. Clemson, MD Associate Professor of Medicine Penn
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More information2016 ESC Heart Failure Guidelines: what is new? Piotr Ponikowski Wroclaw, Poland
2016 ESC Heart Failure Guidelines: what is new? Piotr Ponikowski Wroclaw, Poland Disclosures Consultancy fees and speaker s honoraria from: Amgen, Servier, Novartis, Johnson & Johnson, Merck, Berlin Chemie,
More informationMihai Gheorghiade MD
Mihai Gheorghiade MD Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, Illinois On behalf of: Stephen J Greene MD; Javed Butler MD MPH MBA; Gerasimos Filippatos
More informationCorporate Medical Policy
Corporate Medical Policy ST2 Assay for Chronic Heart Failure File Name: Origination: Last CAP Review: Next CAP Review: Last Review: st_assay_for_chronic_heart_failure 2/2015 4/2018 4/2019 4/2018 Description
More informationKeynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes?
Keynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes? 24 th Annual San Diego Heart Failure Symposium June 1-2, 2018 La Jolla, CA Barry Greenberg, MD Distinguished Professor
More informationCardiorenal Syndrome
Cardiorenal Syndrome Peenida Skulratanasak, M.D. Division of Nephrology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University Definition of Cardiorenal syndrome (CRS) Structural
More informationNew in Heart Failure SGK autumn session 2012
New in Heart Failure SGK autumn session 2012 Roger Hullin Cardiology Department of Internal Medicine Centre Universitaire Hospitaler Vaudois University of Lausanne ESC Heart Failure Guidelines 2012 Classes
More informationThe Cardiorenal Syndrome in Heart Failure
The Cardiorenal Syndrome in Heart Failure Van N Selby, MD Assistant Professor of Medicine Advanced Heart Failure Program, UCSF October 9, 2015 Disclosures None 1 Cardiorenal Syndrome (CRS) A pathophysiologic
More informationPro-enkephalin and Renal Disease. Alan H. Wu, Ph.D. University of California, San Francisco 12 th Annual UCSD Biomarkers of Cardiac Disease
Pro-enkephalin and Renal Disease Alan H. Wu, Ph.D. University of California, San Francisco 12 th Annual UCSD Biomarkers of Cardiac Disease The presenter has received relevant grants and /or consulting
More informationOxford Medicine Online
Oxford Medicine Online The ESC Textbook of Intensive and Acute Cardiovascular Care (2 ed.) Edited by Marco Tubaro, Pascal Vranckx, Susanna Price, and Christiaan Vrints Latest update This online textbook
More informationOverview & Update on the Utilization of the Natriuretic Peptides in Heart Failure
June 28, 2016 Overview & Update on the Utilization of the Natriuretic Peptides in Heart Failure Linda C. Rogers, PhD, DABCC, FACB. Agenda Overview of the Natriuretic Peptides and Efficacy studies Similarities
More informationUrinary biomarkers in acute kidney injury. Max Bell MD, PhD Karolinska University Hospital Solna/Karolinska Institutet
Urinary biomarkers in acute kidney injury Max Bell MD, PhD Karolinska University Hospital Solna/Karolinska Institutet Development of AKI-biomarkers Early markers of AKI, do we need them? GFR drop Normal
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationBiomarkers in Heart Disease. Felix J. Rogers, DO, FACOI April 29, 2018
Biomarkers in Heart Disease Felix J. Rogers, DO, FACOI April 29, 2018 Biomarkers NIH: A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes,
More informationDrugs acting on the reninangiotensin-aldosterone
Drugs acting on the reninangiotensin-aldosterone system John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationCopeptin in heart failure: Associations with clinical characteristics and prognosis
Copeptin in heart failure: Associations with clinical characteristics and prognosis D. Berliner, N. Deubner, W. Fenske, S. Brenner, G. Güder, B. Allolio, R. Jahns, G. Ertl, CE. Angermann, S. Störk for
More informationNew PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0.
New PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0. Measure Steward Measure Name Measure Description Rationale for Adding
More informationAdvanced Care for Decompensated Heart Failure
Advanced Care for Decompensated Heart Failure Sara Kalantari MD Assistant Professor of Medicine, University of Chicago Advanced Heart Failure, Mechanical Circulatory Support and Cardiac Transplantation
More informationDiagnosis is it really Heart Failure?
ESC Congress Munich - 25-29 August 2012 Heart Failure with Preserved Ejection Fraction From Bench to Bedside Diagnosis is it really Heart Failure? Prof. Burkert Pieske Department of Cardiology Med.University
More informationHeart Failure: Combination Treatment Strategies
Heart Failure: Combination Treatment Strategies M. McDonald MD, FRCP State of the Heart Symposium May 28, 2011 None Disclosures Case 69 F, prior MIs (LV ejection fraction 25%), HTN No demonstrable ischemia
More information